HomeCompareSGEN vs VIG

SGEN vs VIG: Dividend Comparison 2026

SGEN yields 0.87% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIG wins by $11.4K in total portfolio value
10 years
SGEN
SGEN
● Live price
0.87%
Share price
$228.74
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.9K
Annual income
$92.54
Full SGEN calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — SGEN vs VIG

📍 VIG pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSGENVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SGEN + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SGEN pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SGEN
Annual income on $10K today (after 15% tax)
$74.32/yr
After 10yr DRIP, annual income (after tax)
$78.66/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, VIG beats the other by $73.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SGEN + VIG for your $10,000?

SGEN: 50%VIG: 50%
100% VIG50/50100% SGEN
Portfolio after 10yr
$26.6K
Annual income
$135.85/yr
Blended yield
0.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SGEN right now

SGEN
Analyst Ratings
14
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$171.82
-24.9% upside vs current
Range: $120.00 — $222.00
Altman Z
23.3
Piotroski
2/9
VIG
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SGEN buys
0
VIG buys
0
No recent congressional trades found for SGEN or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSGENVIG
Forward yield0.87%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$20.9K$32.4K
Annual income after 10y$92.54$179.15
Total dividends collected$902.00$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SGEN vs VIG ($10,000, DRIP)

YearSGEN PortfolioSGEN Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$10,787$87.44$11,304$163.92$517.00VIG
2$11,631$88.15$12,759$166.33$1.1KVIG
3$12,534$88.82$14,382$168.52$1.8KVIG
4$13,500$89.46$16,192$170.52$2.7KVIG
5$14,536$90.05$18,210$172.34$3.7KVIG
6$15,644$90.62$20,460$173.98$4.8KVIG
7$16,830$91.14$22,968$175.48$6.1KVIG
8$18,100$91.64$25,763$176.83$7.7KVIG
9$19,459$92.11$28,878$178.05$9.4KVIG
10$20,913$92.54$32,350$179.15$11.4KVIG

SGEN vs VIG: Complete Analysis 2026

SGENStock

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Full SGEN Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this SGEN vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SGEN vs SCHDSGEN vs JEPISGEN vs OSGEN vs KOSGEN vs MAINSGEN vs DGROSGEN vs NOBLSGEN vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.